Abstract
BackgroundMyeloid-derived suppressor cells (MDSCs) in the tumor microenvironment are potential therapeutic targets in immune checkpoint cancer therapy, particularly for cancers that are unresponsive to anti-PD-1 therapy. It has previously been...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have